CBD for Dog Lymphoma: Comfort Care During Cancer Treatment
Quick Answer: While CBD cannot treat lymphoma, many pet owners report that it may help support comfort during cancer treatment...
Read moreAffiliate Disclosure: This post contains affiliate links. We may earn a commission if you purchase through our links, at no extra cost to you.
Mast cell tumors (MCTs) are one of the most common skin cancers in dogs. While surgery and chemotherapy are primary treatments, CBD offers supportive care benefits that can enhance quality of life during and after treatment.
Mast cells are immune cells that release histamine when activated. Tumors cause excessive histamine release, leading to inflammation, itching, and swelling at the tumor site and throughout the body.
CBD’s anti-inflammatory properties may help reduce the inflammation and itching caused by mast cell degranulation.
Dogs with MCTs often experience anxiety from discomfort. CBD promotes relaxation and calmness during treatment and recovery.
Early research suggests CBD may help modulate immune response, potentially supporting the body’s ability to manage the tumor.
MCTs require aggressive veterinary treatment:
CBD should complement these treatments, not replace them. Always work with your veterinary oncologist.
A typical dose is 2-5mg CBD per pound daily. Some oncologists recommend higher doses (5-10mg/lb) for dogs experiencing significant inflammation or anxiety related to their diagnosis.
Some owners combine CBD with antihistamines (like diphenhydramine) to control histamine-related symptoms. Always discuss combinations with your vet.
For dogs with advanced MCTs or where surgery isn’t possible, CBD becomes a key part of palliative care—helping your dog stay comfortable and present during their remaining time.
After surgery or chemotherapy, CBD can support healing and help manage post-treatment inflammation and discomfort.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Pets’ endocannabinoid systems respond to CBD similarly to humans, though with different metabolism and sensitivity thresholds. Research on pet CBD grows yearly, with veterinary schools now researching cannabinoid therapy. While long-term safety studies are ongoing, short-term use shows excellent safety profiles with minimal side effects in most pets.
Start with conservative doses and monitor your pet closely. For anxiety or mild pain: 1-2mg per 10 lbs daily. For moderate issues: 2-5mg per 10 lbs daily. For severe conditions: up to 5mg per 10 lbs with veterinary guidance. Divide daily dose into morning and evening for consistent symptom control. Track dose and response in a log to optimize over time.
Pet-formulated CBD oils are most popular—easy to dose, quick absorption, and adjustable. CBD treats offer convenience for picky eaters. Topical options work best for localized pain or skin issues. Avoid human products with added ingredients, sweeteners, or flavoring that may upset pet digestion. Always verify third-party testing and contact manufacturers with questions about pet formulations.
CBD works synergistically with traditional veterinary care. For pain: combine with appropriate pain medications as approved by your vet. For anxiety: pair with training, desensitization, and calming environment changes. For skin issues: use with appropriate medicated shampoos and allergen avoidance. CBD enhances the effectiveness of comprehensive care plans.

Interested in finding out more about what’s happening in the world of CBD and Medicinal Cannabis?
Head to CBD World News for the latest scientific research, clinical trials, and business news.
Abstract: Currently, there are no approved pharmacotherapies for addiction to cocaine and other psychostimulant drugs. Several studies have proposed that...
Read moreCredits: Albert Batalla†, Hella Janssen†, Shiral S. Gangadin and Matthijs G. Bossong († These authors contributed equally to this work.)...
Read moreAuthors: Kimberly A. Babson1 & James Sottile 2 & Danielle Morabito1 Publish Date: 27 March 2017 Published by: Springer Science+Business...
Read more